151 related articles for article (PubMed ID: 37233961)
21. Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients.
Wang M; Wei Z; Kong J; Zhao H
Diagn Pathol; 2024 Mar; 19(1):53. PubMed ID: 38509525
[TBL] [Abstract][Full Text] [Related]
22. Imaging and Clinicopathologic Features Associated With Pathologic Complete Response in HER2-positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Dual HER2 Blockade.
Yoon GY; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH; Kim JE; Kim SB
Clin Breast Cancer; 2020 Feb; 20(1):25-32. PubMed ID: 31519449
[TBL] [Abstract][Full Text] [Related]
23. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
Hwang HW; Jung H; Hyeon J; Park YH; Ahn JS; Im YH; Nam SJ; Kim SW; Lee JE; Yu JH; Lee SK; Choi M; Cho SY; Cho EY
Breast Cancer Res Treat; 2019 Jan; 173(2):255-266. PubMed ID: 30324273
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of hormone receptor status conversion following neoadjuvant chemotherapy in a series of operable breast cancer patients.
Tan QX; Qin QH; Yang WP; Lian B; Wei CY
Int J Clin Exp Pathol; 2014; 7(7):4086-94. PubMed ID: 25120787
[TBL] [Abstract][Full Text] [Related]
25. Refining the indications for neoadjuvant chemotherapy for patients with HER2+ breast cancer: A single institution experience.
Pomponio MK; Burkbauer L; Goldbach M; Nazarian SM; Xie F; Clark AS; Matro JM; Fox KR; Shulman LN; Keele LJ; Tchou J
J Surg Oncol; 2020 Mar; 121(3):447-455. PubMed ID: 31919848
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer.
Choi MK; Park YH; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
Cancer Chemother Pharmacol; 2014 Sep; 74(3):521-9. PubMed ID: 25047725
[TBL] [Abstract][Full Text] [Related]
27. Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial.
Lee HB; Han W; Kim SY; Cho N; Kim KE; Park JH; Ju YW; Lee ES; Lim SJ; Kim JH; Ryu HS; Lee DW; Kim M; Kim TY; Lee KH; Shin SU; Lee SH; Chang JM; Moon HG; Im SA; Moon WK; Park IA; Noh DY
Breast Cancer Res Treat; 2020 Jul; 182(1):97-105. PubMed ID: 32418044
[TBL] [Abstract][Full Text] [Related]
28. Impact of hormone receptor, HER2, and Ki-67 status conversions on survival after neoadjuvant chemotherapy in breast cancer patients: a retrospective study.
Chen Y; Liu X; Yu K; Sun X; Xu S; Qiu P; Lv Z; Zhang X; Guo A; Xu Y
Ann Transl Med; 2022 Jan; 10(2):93. PubMed ID: 35282081
[TBL] [Abstract][Full Text] [Related]
29. Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer.
Iwase M; Ando M; Aogi K; Aruga T; Inoue K; Shimomura A; Tokunaga E; Masuda N; Yamauchi H; Yamashita T; Iwata H
Breast Cancer Res Treat; 2020 Apr; 180(3):687-694. PubMed ID: 32140811
[TBL] [Abstract][Full Text] [Related]
30. Can breast MRI predict pathologic response following neoadjuvant chemotherapy for breast cancer? A retrospective cohort study.
Kwak L; Santa-Maria C; Di Carlo P; Mullen LA; Myers KS; Oluyemi E; Panigrahi B; Rossi J; Ambinder EB
Clin Imaging; 2023 Sep; 101():105-112. PubMed ID: 37327550
[TBL] [Abstract][Full Text] [Related]
31. Factors Affecting Pathologic Complete Remission in Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
Choi HJ; Lee JH; Jung CS; Lee JE; Jung YJ; Lee S; Kang SK; Kim HY
Oncology; 2022; 100(10):529-535. PubMed ID: 35882211
[TBL] [Abstract][Full Text] [Related]
32. Pathological measurement and staging of residual breast cancer after neoadjuvant chemotherapy.
Harter D; O'Connor SM; Hertel JD; Calhoun BC
Histopathology; 2023 Sep; 83(3):453-464. PubMed ID: 37256703
[TBL] [Abstract][Full Text] [Related]
33. Characterization of Weakly Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer and Current Treatment Strategies.
Poterala JE; Havighurst T; Braun Wisinski K
Clin Breast Cancer; 2022 Aug; 22(6):611-618. PubMed ID: 35676188
[TBL] [Abstract][Full Text] [Related]
34. Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer.
Yoshida A; Hayashi N; Suzuki K; Takimoto M; Nakamura S; Yamauchi H
J Surg Oncol; 2017 Dec; 116(8):1021-1028. PubMed ID: 28767137
[TBL] [Abstract][Full Text] [Related]
35. Utility of
Lee IH; Lee SJ; Lee J; Jung JH; Park HY; Jeong SY; Lee SW; Chae YS
BMC Cancer; 2020 Nov; 20(1):1106. PubMed ID: 33198673
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis.
Li C; Fan H; Xiang Q; Xu L; Zhang Z; Liu Q; Zhang T; Ling J; Zhou Y; Zhao X; Cui Y
Breast Cancer Res Treat; 2019 Dec; 178(3):497-504. PubMed ID: 31471838
[TBL] [Abstract][Full Text] [Related]
37. How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery?
Petruolo O; Sevilimedu V; Montagna G; Le T; Morrow M; Barrio AV
Ann Surg Oncol; 2021 Jan; 28(1):287-294. PubMed ID: 32514804
[TBL] [Abstract][Full Text] [Related]
38. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy.
Shao Y; Guan H; Luo Z; Yu Y; He Y; Chen Q; Liu C; Zhu F; Liu H
Breast; 2024 Feb; 73():103666. PubMed ID: 38159433
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes.
Hassett MJ; Li H; Burstein HJ; Punglia RS
Breast Cancer Res Treat; 2020 May; 181(1):43-51. PubMed ID: 32185586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
